The United States Food and Drug Administration (USFDA) inspections for Indian pharmaceutical companies have picked up. Following is a summary of inspections undertaken by the USFDA the past few weeks.Sun Pharmaceutical Industries Ltd:Two of Sun’s facilities – Halol and Mohali – got inspected recently. The company’s Halol plant, which is one of their main US facilities with incremental sales of $100-150 million annually.The plant was inspected by the USFDA from August 27 to 31. This was the second consecutive inspection by the FDA of the Halol facility in the past six months.The inspection resulted in the FDA issuing the plant six observations. The observations were likely to be procedural, however, the street was nervous given Halol’s history.The plant had been under warning letter since 2015, which was finally lifted in mid-2018. This latest inspection was not one to fear either.On September 14, two weeks after the inspection closed Sun’s R&D arm, SPARC received approval for speciality eye drug Xelpros, which was filed from the Halol facility.Furthermore, the USFDA has listed the Halol facility as a NAI or No Action Indicated on their FDA site – indicating the plant is in the clear.Additionally, Sun’s Mohali plant also saw a USFDA inspection. The FDA began their inspection at the former Ranbaxy facility on September 10. It continued till September 14 with the plant getting two observations. The street seems sanguine about the observations and in any case Mohali contributes little to US sales.Cadila Healthcare Ltd:A few of the company’s latest inspections included their biologic manufacturing unit at Ahmedabad getting inspected for 10 days – from August 14 to 24. The USFDA issued zero observations to the facility. Cadila’s arm Liva Pharma’s unit also got inspected around the same time. The inspection was from August 20 to 28 and was issued five observations.It was a pre-approval inspection for a product by the USFDA. Impact was limited despite five observations as there is no to little manufacturing for the US markets from it.Lupin Ltd:The company’s active pharmaceutical ingredient (API) facility at Tarapur was inspected by the USFDA from August 27 to 31. It was conducted by three inspectors and received one observation at the end of the inspection.The interesting part of the inspection was that the inspection focused on the company’s overall compliance to manufacturing practices and safety of the manufacturing of its ‘sartan APIs’. Sartan APIs consist of Valsartan, Losartan and Irbesatan.The inspection of the sartan manufacturing was in lieu of the recent recall of the Valsartan API manufactured by Chinese company, ZH Pharma, due to impurities found in it.The FDA concluded the manufacturing of the sartans at Lupin’s facility was safe. Lupin’s Nagpur facility too received an establishment inspection report for an inspection conducted by the FDA in May 2018. The plant is important as it manufactures oral solid dosages.Unichem Laboratories:Past few months have seen two of Unichem’s facilities getting inspected by the USFDA. First, their API facility at Roha, Maharashtra was inspected from August 30 July to 3. The company received four observations during the inspection.But analysts expect this facility to be out of the woods as it has been categorised by the FDA as VAI or Voluntary Action Indicated. That means the company needs to undertake remediation of the observations, but the FDA need nod come and reinspect the facility to give its go ahead.Unichem’s API unit at Pithampur was inspected in July as well – from July 23 to 27, that facility too was issued four observations. The street is still to hear more on the Pithampur facility, but are confident it will be resolved.Unichem’s Ghaziabad plant, a formulation facility received an Establishment Inspection Report in June for an inspection conducted in April 2018.Glenmark Pharmaceuticals and Strides Pharma Science:Glenmark Pharmaceuticals' Baddi unit was inspected by the USFDA. The inspection began on the September 17 and ended around the September 24. The company as per sources received zero observations from the USFDA.Stride’s Bengaluru unit was inspected with three observations in an inspection from August 20 to the 24. Observations are expected to be procedural. Lastly, Cipla’s Goa facility saw a USFDA inspection begin on the September 24 and is expected to have a product specific inspection as well.